Invesco Ltd. Has $148.51 Million Stake in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Invesco Ltd. raised its holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 8.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,535,468 shares of the medical instruments supplier’s stock after buying an additional 118,142 shares during the period. Invesco Ltd.’s holdings in Merit Medical Systems were worth $148,510,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MMSI. Stifel Financial Corp increased its position in shares of Merit Medical Systems by 20.7% during the 3rd quarter. Stifel Financial Corp now owns 28,050 shares of the medical instruments supplier’s stock worth $2,772,000 after purchasing an additional 4,806 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Merit Medical Systems in the third quarter valued at $465,000. MML Investors Services LLC increased its holdings in Merit Medical Systems by 8.5% during the third quarter. MML Investors Services LLC now owns 17,690 shares of the medical instruments supplier’s stock worth $1,748,000 after buying an additional 1,390 shares during the last quarter. Barclays PLC raised its position in Merit Medical Systems by 305.4% during the third quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock worth $11,142,000 after acquiring an additional 84,923 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Merit Medical Systems by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,357,265 shares of the medical instruments supplier’s stock valued at $134,165,000 after acquiring an additional 17,490 shares during the last quarter. 99.66% of the stock is owned by institutional investors.

Insider Transactions at Merit Medical Systems

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 31,320 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the transaction, the chief executive officer now owns 1,086,028 shares in the company, valued at $112,794,868.08. This represents a 2.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian G. Lloyd sold 30,000 shares of Merit Medical Systems stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $102.90, for a total transaction of $3,087,000.00. Following the completion of the sale, the insider now owns 38,945 shares of the company’s stock, valued at approximately $4,007,440.50. The trade was a 43.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,132 shares of company stock valued at $11,139,521. 3.70% of the stock is currently owned by corporate insiders.

Merit Medical Systems Stock Performance

MMSI opened at $92.04 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. The business has a fifty day simple moving average of $101.92 and a 200 day simple moving average of $100.86. Merit Medical Systems, Inc. has a 1 year low of $70.70 and a 1 year high of $111.45. The company has a market capitalization of $5.44 billion, a PE ratio of 45.12, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85.

Analyst Ratings Changes

Several research analysts have recently weighed in on MMSI shares. Wells Fargo & Company lowered their price objective on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $116.00 price target on shares of Merit Medical Systems in a research report on Wednesday. Barrington Research reaffirmed an “outperform” rating and issued a $111.00 price objective on shares of Merit Medical Systems in a research report on Friday. Raymond James lifted their target price on Merit Medical Systems from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 31st. Finally, Canaccord Genuity Group dropped their price target on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus price target of $114.33.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.